SEROSAFE is a medical device company developing a novel surgical drain system designed to reduce complications and improve postoperative recovery. Its product targets the estimated 75.5 million surgical drains used annually in the US, with initial clinical validation underway in a first-in-human trial. The system aims to address the high rates of drain-related complications and negative quality-of-life impacts reported by patients.
Funding
Funding not disclosed
Founders
Product
Problem
Surgical drains, while essential after procedures like breast cancer surgery, cardiac surgery, and orthopedics, are associated with significant patient burden Gangrene. Up to 85% of patients report negative impacts on their quality of life, and complications occur in as many as 25% of cases, leading to costly additional treatments and delayed recovery.
Solution
SEROSAFE provides an improved surgical drain system designed to enhance postoperative recovery and reduce drain-related complications. By integrating insights from surgery and engineering, the company aims to offer a safer and more comfortable solution for patients who require postoperative drainage. The system is being evaluated for its ability to minimize complications and improve patient outcomes during the critical recovery period. Initial clinical validation is underway through a first-in-human clinical trial conducted at a major academic medical center.
Target Audience
The primary audience includes surgeons and medical professionals in fields such as breast cancer, cardiac, orthopedic, and neurosurgery who utilize surgical drains in postoperative care, as well as the patients undergoing these procedures.
Features
- Designed to reduce the incidence of drain-related complications compared to standard devices
- Developed with a focus on improving patient quality of life during the postoperative period
- Engineered through a merger of surgical and engineering expertise for a more effective clinical solution
- Currently undergoing evaluation in a first-in-human clinical trial at a Harvard Medical School teaching hospital